A citation-based method for searching scientific literature

Jonathan Ledermann, Philipp Harter, Charlie Gourley, Michael Friedlander, Ignace Vergote, Gordon Rustin, Clare L Scott, Werner Meier, Ronnie Shapira-Frommer, Tamar Safra, Daniela Matei, Anitra Fielding, Stuart Spencer, Brian Dougherty, Maria Orr, Darren Hodgson, J Carl Barrett, Ursula Matulonis. Lancet Oncol 2014
Times Cited: 841

Jennifer K Litton, Hope S Rugo, Johannes Ettl, Sara A Hurvitz, Anthony Gonçalves, Kyung-Hun Lee, Louis Fehrenbacher, Rinat Yerushalmi, Lida A Mina, Miguel Martin, Henri Roché, Young-Hyuck Im, Ruben G W Quek, Denka Markova, Iulia C Tudor, Alison L Hannah, Wolfgang Eiermann, Joanne L Blum. N Engl J Med 2018
Times Cited: 564

List of shared articles

Times cited

PARP inhibitors in breast and ovarian cancer with BRCA mutations: a meta-analysis of survival.
Fengping Shao, Yaoyun Duan, Yunhe Zhao, Yinguang Li, Jun Liu, Cai Zhang, Shanyang He. Aging (Albany NY) 2021

PARP inhibitors: shifting the paradigm in the treatment of pancreatic cancer.
Devashish Desai, Pushti Khandwala, Meghana Parsi, Rashmika Potdar. Med Oncol 2021

DNA Damage Repair Inhibitor for Breast Cancer Treatment.
Ahrum Min, Kyung-Hun Lee, Seock-Ah Im. Adv Exp Med Biol 2021

Therapeutic Implications of Germline Testing in Patients With Advanced Cancers.
Zsofia K Stadler, Anna Maio, Debyani Chakravarty, Yelena Kemel, Margaret Sheehan, Erin Salo-Mullen, Kaitlyn Tkachuk, Christopher J Fong, Bastien Nguyen, Amanda Erakky,[...]. J Clin Oncol 2021

Understanding and overcoming resistance to PARP inhibitors in cancer therapy.
Mariana Paes Dias, Sarah C Moser, Shridar Ganesan, Jos Jonkers. Nat Rev Clin Oncol 2021

Perspectives on PARP inhibitors as pharmacotherapeutic strategies for breast cancer.
Sun Young Oh, Shafia Rahman, Joseph A Sparano. Expert Opin Pharmacother 2021

Structural Variants at the BRCA1/2 Loci are a Common Source of Homologous Repair Deficiency in High-grade Serous Ovarian Carcinoma.
Ailith Ewing, Alison Meynert, Michael Churchman, Graeme R Grimes, Robert L Hollis, C Simon Herrington, Tzyvia Rye, Clare Bartos, Ian Croy, Michelle Ferguson,[...]. Clin Cancer Res 2021

Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance.
Ling Wang, Qi Wang, Yangchun Xu, Manhua Cui, Liying Han. Curr Drug Targets 2020

Delving into PARP inhibition from bench to bedside and back.
Giovanni Grignani, Alessandra Merlini, Dario Sangiolo, Lorenzo D'Ambrosio, Ymera Pignochino. Pharmacol Ther 2020

[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications].
Meriem Koual, Géraldine Perkins, Nicolas Delanoy, Céline Crespel, Jacques Medioni, Huyên-Thu Nguyen-Xuan, Nathalie Douay-Hauser, Hélène Blons, Marie-Aude Le Frère-Belda, Diane Molière,[...]. Ann Pathol 2020

The antitumorigenic roles of BRCA1-BARD1 in DNA repair and replication.
Madalena Tarsounas, Patrick Sung. Nat Rev Mol Cell Biol 2020

Genomic Alteration in Metastatic Breast Cancer and Its Treatment.
Allen Li, Stephen M Schleicher, Fabrice Andre, Zahi I Mitri. Am Soc Clin Oncol Educ Book 2020

Poly (ADP-Ribose) Polymerase Inhibitors: Talazoparib in Ovarian Cancer and Beyond.
Stergios Boussios, Charlotte Abson, Michele Moschetta, Elie Rassy, Afroditi Karathanasi, Tahir Bhat, Faisal Ghumman, Matin Sheriff, Nicholas Pavlidis. Drugs R D 2020